Intracerebral Hemorrhage in Southern Norway – A Hospital-Based Incidence StudyTveiten A.a · Ljøstad U.a · Mygland Å.a, b, d · Thomassen L.c, d · Pripp A.H.e · Naess H.c
Departments of aNeurology and bHabilitation, Sørlandet Sykehus Kristiansand, Kristiansand, cDepartment of Neurology, Bergen University Hospital, and dInstitute of Clinical Medicine, University of Bergen, Bergen, and eBiostatistics and Epidemiology Unit, Oslo University Hospital, Oslo, Norway
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Background/Aims: Newer Scandinavian data on intracerebral hemorrhage (ICH) are scarce. We aimed at providing updated community-based data on the incidence, characteristics and outcome of ICH leading to hospitalization in the southernmost region in Norway. Methods: We analyzed data from all consecutive patients hospitalized with a first-ever ICH in the five-year period 2005–2009 in a well-defined area served by one single hospital. Cases were found by computerized search in a register covering all in- and outpatients. Results: Adjusted to the standard European population the annual incidence rate per 100,000 was 16.9 for men, 8.8 for women (p < 0.001) and 12.5 for both sexes. The incidence rates rose continuously with increasing age through all age groups in both sexes. The proportion with warfarin-associated ICH was 26.9%. The overall 30-day case fatality rate was 36.6%. The hematoma location was lobar in 36.6%, deep cerebral in 45.5%, cerebellar in 9.7%, and brain stem in 8.2%. Conclusions: The incidence of ICH in the southernmost region in Norway is in the midrange in Europe and lower than in previous Scandinavian studies. Men are at higher risk than women. The proportion with warfarin-associated ICH is higher than previously reported from Scandinavia.
© 2012 S. Karger AG, Basel
- Heuschmann PU, Di Carlo A, Bejot Y, Rastenyte D, Ryglewicz D, Sarti C, Torrent M, Wolfe CD: Incidence of stroke in Europe at the beginning of the 21st century. Stroke 2009;40:1557–1563.
- Sacco S, Marini C, Toni D, Olivieri L, Carolei A: Incidence and 10-year survival of intracerebral hemorrhage in a population-based registry. Stroke 2009;40:394–399.
- Nilsson OG, Lindgren A, Stahl N, Brandt L, Saveland H: Incidence of intracerebral and subarachnoid haemorrhage in southern Sweden. J Neurol Neurosurg Psychiatry 2000;69:601–607.
- Ellekjaer H, Holmen J, Indredavik B, Terent A: Epidemiology of stroke in Innherred, Norway, 1994 to 1996. Incidence and 30-day case-fatality rate. Stroke 1997;28:2180–2184.
- van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ: Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. Lancet Neurol 2010;9:167–176.
- Appelros P, Nydevik I, Seiger A, Terent A: High incidence rates of stroke in Orebro, Sweden: further support for regional incidence differences within Scandinavia. Cerebrovasc Dis 2002;14:161–168.
- Hart RG, Boop BS, Anderson DC: Oral anticoagulants and intracranial hemorrhage. Facts and hypotheses. Stroke 1995;26:1471–1477.
- Gage BF, Birman-Deych E, Kerzner R, Radford MJ, Nilasena DS, Rich MW: Incidence of intracranial hemorrhage in patients with atrial fibrillation who are prone to fall. Am J Med 2005;118:612–617.
- Rosand J, Eckman MH, Knudsen KA, Singer DE, Greenberg SM: The effect of warfarin and intensity of anticoagulation on outcome of intracerebral hemorrhage. Arch Intern Med 2004;164:880–884.
- Flaherty ML, Haverbusch M, Sekar P, Kissela BM, Kleindorfer D, Moomaw CJ, Broderick JP, Woo D: Location and outcome of anticoagulant-associated intracerebral hemorrhage. Neurocrit Care 2006;5:197–201.
- Zia E, Engstrom G, Svensson PJ, Norrving B, Pessah-Rasmussen H: Three-year survival and stroke recurrence rates in patients with primary intracerebral hemorrhage. Stroke 2009;40:3567–3573.
National population register. http://www.norway.no/temaside/tema.asp?stikkord=94303.
- Kothari RU, Brott T, Broderick JP, Barsan WG, Sauerbeck LR, Zuccarello M, Khoury J: The ABCs of measuring intracerebral hemorrhage volumes. Stroke 1996;27:1304–1305.
Statistics Norway. http://www.ssb.no/en/.
- Sjalander A, Engstrom G, Berntorp E, Svensson P: Risk of haemorrhagic stroke in patients with oral anticoagulation compared with the general population. J Intern Med 2003;254:434–438.
- Cervera A, Amaro S, Chamorro A: Oral anticoagulant-associated intracerebral hemorrhage. J Neurol 2012;259:212–224.
The Norwegian Prescription Database. http://www.norpd.no/.
- Huhtakangas J, Tetri S, Juvela S, Saloheimo P, Bode MK, Hillbom M: Effect of increased warfarin use on warfarin-related cerebral hemorrhage: a longitudinal population-based study. Stroke 2011;42:2431–2435.
- Steiner T, Rosand J, Diringer M: Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions. Stroke 2006;37:256–262.
- Flaherty ML, Woo D, Haverbusch M, Sekar P, Khoury J, Sauerbeck L, Moomaw CJ, Schneider A, Kissela B, Kleindorfer D, Broderick JP: Racial variations in location and risk of intracerebral hemorrhage. Stroke 2005;36:934–937.
- Tveiten A, Mygland A, Ljostad U, Thomassen L: Intravenous thrombolysis for ischaemic stroke: short delays and high community-based treatment rates after organisational changes in a previously inexperienced centre. Emerg Med J 2009;26:324–326.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.